Her-Vaxx was developed 2010-2013, B-Vaxx a bit earlier. B-Vaxx entered phase 1 in 2014 and its ph2 is still going with an increased patient number.
Her-Vaxx, using some experiences from B-Vaxx was fine tuned in 2017 / 2018. PD1-Vaxx is based on that experiences, developed about 2017/2019, first known as Key-Vaxx, then renamed PD1-Vaxx. With Her-Vaxx already making its mark, higher expectations for PD1-Vaxx are warranted and so far ph1 cohort 1/2 have proven us right.
And CF33 is not even in the market's mind / radar.
GLTA
-
- There are more pages in this discussion • 5,302 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |